3-Fluoro-4-methylbenzonitrile | CAS:170572-49-3

We serve 3-Fluoro-4-methylbenzonitrile CAS:170572-49-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Fluoro-4-methylbenzonitrile

Chemical Name:3-Fluoro-4-methylbenzonitrile
CAS.NO:170572-49-3
Synonyms:3-Fluoro-p-tolunitrile; 
4-methyl-3-fluorobenzonitrile;
Molecular Formula:C8H6FN
Molecular Weight:135.13800
 
Physical and Chemical Properties:
Density:1.11;
Melting point:48-50oC;
Boiling point:204oC;
Flash point:90.3oC;
Index of Refraction:1.508;
 
Specification:
Appearance:Off-white to beige crystalline solid
Purity(GC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis
 



Contact us for information like 3-Fluoro-4-methylbenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-methyl-3-fluorobenzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Fluoro-4-methylbenzonitrile Use and application,3-Fluoro-4-methylbenzonitrile technical grade,usp/ep/jp grade.


Related News: New Zealand citizens and permanent residents and their immediate family members will still be able to enter — but must self-isolate for 14 days after arriving back into the country.2,3-Difluorotoluene manufacturer New Zealand citizens and permanent residents and their immediate family members will still be able to enter — but must self-isolate for 14 days after arriving back into the country.(aminomethyl)phosphonic acid supplier New Zealand citizens and permanent residents and their immediate family members will still be able to enter — but must self-isolate for 14 days after arriving back into the country.4-(Methylsulfonyl)phenylboronic Acid vendor Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.